Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Interest Expense

Cost of servicing the company's debt during the period.

Valneva SENASDAQ: VALN

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense dips below year-ago levels

Q1 FY2026 interest expense of €5.09M fell 14.8% year over year, behind the +78.9% change in trailing-twelve-month interest expense. Sequentially, it fell 79.3% from the prior quarter. Over 3 fiscal years it compounded at +30.0% a year.

Context

  • Interest expense amounted to 24.0% of revenue in FY2025, up 9.8 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -14.8% toward the trailing-twelve-month pace of +78.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€5.09M-79.3% QoQ
Last fiscal yearDec 2025
€41.9M+74.7% YoY
LTMMar 2026
€41.01M+78.9% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.8%——
1 year+74.7%——
3-year CAGR+30.0%——
5-year CAGR——
10-year CAGR——

Interest Expense history

EUR · from the income statement

Latest · FY2025
41.9M EUR
Year-over-year change
+74.7%
4-year CAGR
+25.4%

Interest Expense vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +78.9% is the 2nd highest of 4, against a peer median of -12.5%.
  • Interest expense amounts to 26.2% of revenue for VALN, versus a peer median of 1.0%.
VALN Competitors
Interest Expense for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$87.69M USD-12.5%+33.6%48.0%
VALNValneva SELTM Mar 2026€41.01M EUR+78.9%+30.0%26.2%
MRNAModerna, Inc.LTM Sep 2026$25M USD+212.5%-29.9%1.0%
NVAXNovavax, Inc.LTM Mar 2026$11.92M USD-45.0%+4.3%2.0%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD——0.0%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD——0.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
Peer median (excluding VALN) —-12.5%+4.3%1.0%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.